Cargando…

1473. Structured Patient Interview in Complicated Urinary Tract Infections to Assess Clinical Outcomes vs. Investigator’s Evaluation in the APEKS-cUTI Study

BACKGROUND: Based on the 2009 US FDA guidance, patient-reported outcome (PRO) measures are recommended in clinical study designs for certain indications to evaluate response to therapy from the patient’s perspective, and a PRO was recommended in the final complicated urinary tract infection (cUTI) g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Portsmouth, Simon, Toyoizumi, Kiichiro, Den Nagata, Tsutae, Tillotson, Glenn S, Echols, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810093/ http://dx.doi.org/10.1093/ofid/ofz360.1337

Ejemplares similares

Structured patient interview to assess clinical outcomes in complicated urinary tract infections in the APEKS-cUTI study: pilot investigation
por: Portsmouth, Simon, et al.
Publicado: (2021)

666. Efficacy and Safety of Cefiderocol According to Renal Impairment in Patients With Complicated Urinary Tract Infection (cUTI) in a Phase 2 Study
por: Portsmouth, Simon, et al.
Publicado: (2019)

1521. Heterogeneity of Recent Phase 3 cUTI Clinical Trials with New Antibiotics
por: Bass, Almasa, et al.
Publicado: (2018)

1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies
por: Takemura, Miki, et al.
Publicado: (2020)

Heterogeneity of Recent Phase 3 Complicated Urinary Tract Infection Clinical Trials
por: Portsmouth, Simon, et al.
Publicado: (2021)

1271. Efficacy and Safety of Cefiderocol and Best Available Therapy in Patients with Serious Infections Caused by Carbapenem-Resistant Gram-Negative Infections: Results of the Pathogen-Focused Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2020)

1044 Efficacy of Ceftolozane/Tazobactam vs Levofloxacin in the Treatment of Complicated Urinary Tract Infections (cUTI) caused by Levofloxacin-resistant Pathogens: Results from the ASPECT-cUTI Trial
por: Sakoulas, George, et al.
Publicado: (2014)

Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study
por: Skaar, Eric P., et al.
Publicado: (2022)

US FDA’s Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication
por: Echols, Roger M, et al.
Publicado: (2021)

874 Risk Factors for Complicated Urinary Tract Infection (cUTI) due to Pseudomonas
por: Mcgregor, Jessina C., et al.
Publicado: (2014)

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
por: Matsunaga, Yuko, et al.
Publicado: (2020)

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies( )
por: Timsit, Jean Francois, et al.
Publicado: (2022)

1031 Comparative Epidemiology of Complicated Urinary Tract Infections (cUTI) by Age among US Hospitals
por: Mocarski, Michelle, et al.
Publicado: (2014)

Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens – The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
por: Bassetti, Matteo, et al.
Publicado: (2019)

1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020)

1040 Describing Antibiotic Utilization Patterns and Healthcare Costs for Ambulatory and Inpatient/ED Treatment of Complicated Urinary Tract Infection (cUTI)
por: Karve, Sudeep, et al.
Publicado: (2014)

LB4. Efficacy and Safety of Cefiderocol vs. High-Dose Meropenem in Patients with Nosocomial Pneumonia—Results of a Phase 3, Randomized, Multicenter, Double-Blind, Non-Inferiority Study
por: Wunderink, Richard G, et al.
Publicado: (2019)

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
por: Nordmann, Patrice, et al.
Publicado: (2022)

Genotypic characteristics of Uropathogenic Escherichia coli isolated from complicated urinary tract infection (cUTI) and asymptomatic bacteriuria—a relational analysis
por: Maniam, Lalitha, et al.
Publicado: (2023)

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials
por: Longshaw, Christopher, et al.
Publicado: (2022)

1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections
por: Matsunaga, Yuko, et al.
Publicado: (2020)

1670. Clinical Characteristics and Demographics of Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

1682. Health Resource Utilization in Patients with Complicated Urinary Tract Infections (cUTI) and Antibiotic Resistance or Treatment Failure: A Retrospective Database Analysis
por: Sulham, Katherine, et al.
Publicado: (2020)

2513. CERTAIN-1 Subgroup Analysis: A Phase 3 Study of Cefepime-Taniborbactam Efficacy in the Treatment of Complicated Urinary Tract Infections (cUTI)
por: Dorr, Mary Beth, et al.
Publicado: (2023)

Frailty associated urinary tract infections (FaUTIs)
por: Kostakopoulos, Nikolaos A., et al.
Publicado: (2021)

Pathogen-focused Clinical Development to Address Unmet Medical Need: Cefiderocol Targeting Carbapenem Resistance
por: Echols, Roger, et al.
Publicado: (2019)

2523. Outcomes by Resistance Phenotype and Genotype among Baseline Pathogen in Patients with Complicated Urinary Tract Infection (cUTI) in the Phase 3 CERTAIN-1 Study
por: Moeck, Greg, et al.
Publicado: (2023)

Urinary tract infections (UTIs) or genital tract infections (GTIs)? It's the diagnostics that count
por: Behzadi, Payam, et al.
Publicado: (2019)

124. Microbiological Outcomes With Plazomicin (PLZ) Versus Meropenem (MEM) in Patients With Complicated Urinary Tract Infections (cUTI), Including Acute Pyelonephritis (AP) in the EPIC Study
por: Keepers, Tiffany R, et al.
Publicado: (2018)

1683. Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals
por: Lodise, Thomas, et al.
Publicado: (2020)

731. CERTAIN-1: A Phase 3 Study of Cefepime-Taniborbactam Efficacy and Safety in the Treatment of Complicated Urinary Tract Infections (cUTI), including Acute Pyelonephritis (AP)
por: McGovern, Paul C, et al.
Publicado: (2022)

1430. Descriptive Epidemiology of Emergency Department Visits with cUTI in the US, 2012-2018
por: Zilberberg, Marya, et al.
Publicado: (2021)

Urinary tract infection (UTI) and infection control in municipal nursing homes
por: Andersen, A-M, et al.
Publicado: (2011)

The role of toll-like receptors (TLRs) in urinary tract infections (UTIs)
por: Behzadi, Elham, et al.
Publicado: (2016)

Paper and thread as media for the frugal detection of urinary tract infections (UTIs)
por: Hasandka, Amrutha, et al.
Publicado: (2021)

720. Efficacy of Fosfomycin for Injection (FOS) vs. Piperacillin–Tazobactam (PIP-TAZ) in Adults with Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP): ZEUS Study Outcomes in Patients With Reduced Study Drug Susceptibility
por: Kaye, Keith S, et al.
Publicado: (2019)

1578. Treatments for complicated urinary tract infections (cUTI) caused by multidrug resistant (MDR) Gram-negative (GN) pathogens- a systematic review and network meta-analysis (NMA)
por: Reason, Tim, et al.
Publicado: (2020)

260 Ceftolozane/Tazobactam for the Treatment of cUTI and cIAI Caused by ESBL-producing Enterobacteriaceae
por: Popejoy, Myra, et al.
Publicado: (2014)

Best practices in treatment of urinary tract infections (UTIs): “low-hanging fruit”
Publicado: (2019)

Recurrent Urinary Tract Infections: Unraveling the Complicated Environment of Uncomplicated rUTIs
por: Josephs-Spaulding, Jonathan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mn2dn5mh5f6t8bt4fb3ehrqv7i